{'fraction_non_alphanumeric': 0.049273021001615507, 'fraction_numerical': 0.02827140549273021, 'mean_word_length': 5.38659793814433, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles

Abstract Context: Liver cancer is widespread liver malignancy in the world, for an estimated one million deaths annually. Objective: In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma. Materials and methods: Lactobionic acid conjugated PLGA was used to prepare LDNPs using modified emulsion diffusion method. Results: They were characterised for particle morphology, particle size (below 150 nm), zeta potential and polydispersity index (PDI ∼0.35), entrapment efficiency (∼60.23%), and cumulative percent drug release. Discussion: LDNPs in ex-vivo cell line studies on human cancer cell line HepG2 exhibited significantly higher cytotoxicity compared to 5-FU and DNPs (unconjugated PLGA NPs) with growth inhibition 50% (GI50) of 66.7 µg/mL, 50.2 µg/mL and 35.5 µg/mL, respectively. In vivo studies exhibited higher drug concentration about 37.52 ± 0.68% in liver as compared to other organs and plasma. Conclusion: Thus, LDNPs showed high drug loading, specificity, biocompatibility and efficacy in treatment of liver cancer.